Indications |
Subcutaneous Assisted reproductive technologies Adult: As acetate: equiv to 0.25 mg cetrorelix either in the morning beginning on the day 5 or 6 of ovarian stimulation or in the evening beginning on day 5, and continued until ovulation induction. Alternatively, a single dose equiv to 3 mg cetrorelix on day 7,; if follicle growth does not allow ovulation induction within 4 days, additional doses of 250 mcg once daily may be given until the day of ovulation induction. |
Contraindications |
Hypersensitivity. Moderate to severe renal or hepatic impairment. Women with severe allergic conditions. Pregnancy and lactation; |
Warnings / Precautions |
Women with active allergic conditions or a history of allergies; childn; elderly >65 yrs |
Adverse Reactions |
Mild and transient reactions at Inj site, nausea, headache, ovarian hyperstimulation syndrome, systemic hypersensitivity reactions. |
Lab Interactions |
Increased ALT, AST, GGT and alkaline phosphatase. |
Mechanism of Actions |
Cetrorelix, a synthetic decapeptide analog of naturally occurring gonadorelin, is a gonadorelin antagonist. It competitively blocks gonadorelin receptors on the anterior piyuitary gonadotroph and the subsequent transduction pathway, inducing a rapid, reversible suppression of gonadotrophin secretion. Duration: 4 days for a single 3-mg dose. |
ATC Classification |
H01CC02 - cetrorelix ; Belongs to the class of anti-gonadotropin-releasing hormones. Used in hypothalamic hormone preparations. |
Available As |
|
Cetrorelix
Post Review about Cetrorelix Click here to cancel reply.
Cetrorelix Containing Brands
Cetrorelix is used in following diseases
Drug - Drug Interactions of Cetrorelix
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.